Basic research on neonatal Fc receptor (FcRn) affinity to establish half-life extension technology of therapeutic antibodies
| Project/Area Number |
15K08087
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | National Institute of Health Sciences |
|---|
Principal Investigator |
Suzuki Takuo 国立医薬品食品衛生研究所, 生物薬品部, 主任研究官 (10415466)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
橋井 則貴 国立医薬品食品衛生研究所, 生物薬品部, 室長 (20425672)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | FcRn / 抗体医薬品 / 表面プラズモン共鳴 / Fcγ受容体 / 半減期延長 / アミノ酸改変 / HDX/MS / 水素重水素交換／質量分析 |
|---|
| Outline of Final Research Achievements |
Therepeutic antibodies are protected from degradation by binding to neonatal Fc receptor (FcRn) in endosome and are recycled into plasma, thereby having long half-lives. To prolong the half-lives additionally with the aim of reducing dose and frequency, amino acids-substituted antibodies having high affinity to FcRn are being developed. However, there are cases that the half-lives of the antibodies are not prolonged. As basic researches on neonatal Fc receptor (FcRn) affinity to establish half-life extension technology of therapeutic antibodies, we performed the studies on the binding between FcRn and amino acids-substituted antibodies, and investigated the changes of the conformation and function of IgG (i.e. binding to Fc gamma receptors) by amino acids substitution for raising the affinity to FcRn.
|
Report
(4 results)
Research Products
(2 results)
